Myeloproliferative neoplasms clinical trials
If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information.
For more information on myeloproliferative neoplasms clinical trials, get in contact with our Haem C team This email address is being protected from spambots. You need JavaScript enabled to view it..
Open and Recruiting Clinical Trials
INCA
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Trial ID
NCT05936359
Cancer type
Myeloproliferative neoplasms
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
SLN124-004
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
Trial ID
NCT05499013
Cancer type
Polycythemia vera
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
KER050-MF-301
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis
Trial ID
NCT05037760
Cancer type
Myelofibrosis
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to ClinicalTrials.gov.
CGT9486-20-201
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis
Trial ID
NCT04996875
Cancer type
Systemic mastocytosis
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
